Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancerEverett J. Moding, Maximilian Diehn, Carol D. Jones et al.|Nature Cancer|2020Cited by 369
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionBarzin Y. Nabet, Maximilian Diehn, Mohammad Shahrokh Esfahani et al.|Cell|2020Cited by 360
<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase InhibitionMichael S. Binkley, Maximilian Diehn, Young-Jun Jeon et al.|Cancer Discovery|2020Cited by 172
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLCMatthew D. Hellmann, Maximilian Diehn, Barzin Y. Nabet et al.|Clinical Cancer Research|2020Cited by 123
Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genesJason D. Merker, Jason Gotlib, Krishna M. Roskin et al.|Haematologica|2013Cited by 12